Many patients have long-lasting remissions with CAR T therapies.
Unlike surgeries or radiations, CAR T uses the body's own modified cells to fight cancer.
Each treatment is tailored to the patient's unique cellular structure, ensuring higher efficacy.
CAR T therapies are specifically designed to target individual cancer cells, sparing healthy cells.
CAR T therapies have not only transformed patient lives but have also garnered the attention and endorsement of leading health organizations and experts worldwide. Esteemed institutions and cancer treatment centers have adopted and advocated for CAR T, underscoring its potential in reshaping the future of cancer care.
Several countries, including the USA, Canada, Germany, France, Spain, UK, Italy, Israel, Australia, Singapore, and China, offer CAR T therapy.
Specific targeted CAR T cells can induce prolonged remissions in patients with particular malignancies, often with low long-term toxicities, and potentially curative for a subset of patients.
CAR T therapies represent a remarkable blend of cellular therapy, immunotherapy, and gene therapy. They are not merely drugs, but "living" medicines infused into patients. As immunotherapies, they harness the body's immune cells to fight cancer cells. Moreover, they stand as pioneering gene therapies, with genetically engineered lymphocytes targeting and combating the disease.
CAR T therapies have marked a new era in oncological care, with commercially approved treatments for certain cancers and numerous clinical trials paving the way for future advancements.
